New hope for kidney transplant patients: safer cholesterol drug under study

This study tested a drug called evolocumab (Repatha) to lower high cholesterol in kidney transplant recipients. High cholesterol is common after transplant and raises heart disease risk, but standard statin drugs can cause side effects in these patients. The study enrolled 81 adults who were at least one year post-transplant and had high LDL cholesterol. Researchers measured how much LDL cholesterol dropped after 12 months of treatment to see if evolocumab is a safe and effective option for this group.